Anxiolytic Effects of Repeated Cannabidiol Treatment in Teenagers With Social Anxiety Disorders

Nobuo Masataka, Nobuo Masataka

Abstract

Accumulated evidence indicates that cannabidiol (CBD), a nonpsychotomimetic and nonaddictive main component of the Cannabis sativa plant, reverses anxiety-like behavior. The purpose of the present study was to assess the efficacy of CBD treatment for Japanese late teenagers with social anxiety disorder (SAD). Thirty-seven 18-19-year-old Japanese teenagers with SAD and avoidant personality disorder received, in a double-blind study, cannabis oil (n = 17) containing 300 mg CBD or placebo (n = 20) daily for 4 weeks. SAD symptoms were measured at the beginning and end of the treatment period using the Fear of Negative Evaluation Questionnaire and the Liebowitz Social Anxiety Scale. CBD significantly decreased anxiety measured by both scales. The results indicate that CBD could be a useful option to treat social anxiety.

Keywords: avoidant personality disorder; cannabidiol; cannabinoid; cannabis; social anxiety disorder; social phobia; social withdrawal.

Copyright © 2019 Masataka.

Figures

Figure 1
Figure 1
Scores of Fear of Negative Evaluation Questionnaire (FNE) in the participants who received the intervention with cannabidiol (CBD; n = 17) and in the participants who received the intervention with placebo (Placebo; n = 20). The participants were evaluated before (Pre) and after (Post) treatment. Error bars represent SDs. * indicates significant difference from pretreatment measurement.
Figure 2
Figure 2
Scores of Liebowitz Social Anxiety Scale (LSAS) in the participants who received the intervention with cannabidiol (CBD; n = 17) and in the participants who received the intervention with placebo (Placebo; n = 20). The participants were evaluated before (Pre) and after (Post) treatment. Error bars represent SDs. * indicates significant difference from pretreatment measurement.

References

    1. American Psychiatric Association (2000). Diagnostic and statistical manual of mental disorders. 4th Edn. (Washington, DC: American Psychiatric Association, Text Revision; ), 1–302.
    1. Antony M. M., Rowa K. (2008). Social anxiety disorder. (Cambridge, MA: Hogrefe; ), 1–177.
    1. Bergamaschi M. M., Queiroz R. H. C., Chagas M. H. N., de Oliveira D. C. G., De Martinis B. S., Kapczinski F., et al. (2011). Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients. Neuropsychopharmcology 36, 1219–1226. 10.1038/npp.2011.6
    1. Blessing E. M., Steenkamp M. M., Manzanares J., Marmar C. R. (2015). Cannabidiol as a potential treatment for anxiety disorders. Neurotherapeutics 12, 825–836. 10.1007/s13311-015-0387-1
    1. Brown T. A., Campbell L. A., Lehman C. L., Grisham J. R., Mancill R. B. (2001). Current and lifetime comorbidity of the DSM-IV anxiety and mood disorders in a large clinical sample. J. Abnorm. Psychol. 110, 49–58. 10.1037//0021-843x.110.4.585
    1. Costa B., Trovato A. E., Comelli F., Giagnoni G., Colleoni M. (2007). The non-psychoactive cannabis constituent cannabidiol is an orally effective therapeutic agent in rat chronic inflammatory and neuropathic pain. Eur. J. Pharmacol. 556, 75–83. 10.1016/j.ejphar.2006.11.006
    1. Craske M. G., Stein M. B., Eley T. C., Milad M. R., Holmes A., Rapes R. M., et al. (2017). Anxiety disorders. Nat. Rev. Dis. Prim. 3:17024. 10.1038/nrdp.2017.24
    1. Crippa J. A., Derenusson G. N., Ferrari T. B., Wichert-Ana L., Duran F. L., Martin-Santos R., et al. (2011). Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report. J. Psychopharmacol. 25, 121–130. 10.1177/0269881110379283
    1. De Gregorio D., McLaughlin R. J., Posa L., Ochoa-Sanchez R., Enns J., Lopez-Canul M., et al. (2019). Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain. Pain 160, 136–150. 10.1097/j.pain.0000000000001386
    1. Devinsky O., Marsh E., Friedman D., Thiele E., Laux L., Sullivan J., et al. (2016). Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. Lancet Neurol. 15, 270–278. 10.1016/S1474-4422(15)00379-8
    1. Di Nardo P. A., Brown T. A., Barlow D. H. (1994). Anxiety disorders interview schedule for DSM-IV (ADIS-IV). Albany, NY: Graywind, 1–195.
    1. First M. B., Gibbon M., Spitzer R. L., Williams J. B. W., Benjamin L. S. (1997). User’s guide for the structured clinical interview for DSM-IV Axis II personality disorders (SCD-II). (Washington, DC: American Psychiatric Press; ), 1–176.
    1. Kessler R. C., Berglund P., Demier O., Jin R., Merikangas K. R., Walters E. E. (2005). Lifetime prevalence and age-of-onset distribution of DSM-IV-R psychiatric disorders in the National Comorbidity Survey Replication. Arch. Gen. Psychiatry 49, 273–281. 10.1001/archpsyc.62.6.593
    1. Liebowitz M. R. (1987). Social phobia. Mod. Probl. Pharm. Psychiatry 22, 141–173.
    1. Masataka N. (2003). The onset of language. (Cambridge: Cambridge University Press; ), 1–281.
    1. McGuire P., Robson P., Cubala W. J., Vasile D., Morrison P. D., Barron R., et al. (2018). Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: a multicenter randomized control trial. Am. J. Psychiatry 175, 225–231. 10.1176/appi.ajp.2017.17030325
    1. Merikangas K. R., He J. P., Burstein M., Svendsen J., Avenevoll S., Case B., et al. (2011). Service utilization for lifetime mental disorders in U.S. adolescents: results of the National Comorbidity Survey-Adolescent Supplement (NCS-A). J. Am. Acad. Child Adolesc. Psychiatry 50, 32–45. 10.1016/j.jaac.2010.10.006
    1. Nordahl H. M., Vogel P. A., Morken G., Stiles T. C., Sandvik P., Wells A. (2016). Paraxetine, cognitive therapy or their combination in the treatment of social anxiety disorder with and without avoidant personality disorder: a randomized clinical trial. Psychother. Psychosom. 85, 346–356. 10.1159/000447013
    1. Ogino T. (2004). Managing categorization and social withdrawal in Japan: rehabilitation process in a private support group for hikikomorians. Int. J. Soc. Psychiatry 13, 120–133. 10.1111/j.1475-6781.2004.00057.x
    1. Parker L. A., Kwiatokowska M., Mechoulam R. (2006). Delta-9-tetrahydrocannabinol and cannabidiol, but not ondansetron, interfere with conditioned retching reactions elicited by a lithium-paired context in Suncus murinus: an animal model of anticipatory nausea and vomiting. Physiol. Behav. 87, 66–71. 10.1016/j.physbeh.2005.08.045
    1. Ryan J. L., Warner C. M. (2012). Treating adolescents with social anxiety disorders in schools. Child Adolesc. Psychiatr. Clin. N. Am. 21:1050118. 10.1016/j.chc.2011.08.011
    1. Saito T. (2007). Why hikikomori is cured? Tokyo: Chuo Hoki Press, 1–138.
    1. Scuderi C., Filippis D. D., Iuvone T., Blasio A., Steardo A., Esposito G. (2009). Cannabidiol in medicine: a review of its therapeutic potential in CNS disorders. Psychother. Res. 23, 597–602. 10.1002/ptr.2625
    1. Somers J. M., Goldner E. M., Waraich P., Hsu L. (2006). Prevalence and incidence studies of anxiety disorders: a systematic review of the literature. Can. J. Psychiatry 51, 110–113. 10.1177/070674370605100206
    1. Teo A. R. (2010). A new form of social withdrawal in Japan: a review of Hikikomori. Int. J. Soc. Psychiatry 56, 175–185. 10.1177/0020764008100629
    1. Watson D., Friend R. (1969). Measurement of social-evaluative anxiety. J. Consult. Clin. Psychol. 33, 448–457. 10.1037/h0027806
    1. Whiting P. F., Wolff R. F., Deshepande S., Di Nisio M., Duffy S., Hemandez A. V., et al. (2015). Cannabinoids for medical use: a systematic review and meta-analysis. JAMA 313, 2456–2473. 10.1001/jama.2015.6358
    1. Zuardi A. W., Cosme R. A., Graeff F. G., Guimaraes F. S. (1993). Effects of ipsapirone and cannabidiol on human experimental anxiety. J. Psychopharmacol. 7, 82–88. 10.1177/026988119300700112

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel